# Relapsed B-Cell Non Hodgkin Lymphoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/relapsed-b-cell-non-hodgkin-lymphoma

> 4 upcoming FDA catalysts in relapsed B-Cell Non Hodgkin Lymphoma: cd19 t-hank- iv administration (IBRX) on May to Aug 2027 (topline data readout); cd19 t-hank- iv administration (IBRX) on May 2027 (primary completion); N-803 (IBRX) on December 2027 (primary completion); N-803 (IBRX) on Dec 2027 to Mar 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May to Aug 2027 | [Cd19 t-hank- iv administration topline data readout](https://sec-api.dev/pdufa/cd19-t-hank-iv-administration) | IBRX | Relapsed B-Cell Non Hodgkin Lymphoma | scheduled | "NCT07125872 (Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05-25 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07125872)) |
| May 2027 | [Cd19 t-hank- iv administration primary completion](https://sec-api.dev/pdufa/cd19-t-hank-iv-administration) | IBRX | Relapsed B-Cell Non Hodgkin Lymphoma | scheduled | "NCT07125872 (Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05-25 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07125872)) |
| December 2027 | [N-803 primary completion](https://sec-api.dev/pdufa/n-803) | IBRX | Relapsed B-Cell Non-Hodgkin Lymphoma | scheduled | "NCT07477366 (Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07477366)) |
| Dec 2027 to Mar 2028 | [N-803 topline data readout](https://sec-api.dev/pdufa/n-803) | IBRX | Relapsed B-Cell Non-Hodgkin Lymphoma | scheduled | "NCT07477366 (Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07477366)) |

## Drugs

- [Cd19 t-hank- iv administration](https://sec-api.dev/pdufa/cd19-t-hank-iv-administration) (IBRX)
- [N-803](https://sec-api.dev/pdufa/n-803) (IBRX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/relapsed-b-cell-non-hodgkin-lymphoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Relapsed B-Cell Non Hodgkin Lymphoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/relapsed-b-cell-non-hodgkin-lymphoma

```bibtex
@misc{secapidev_indications_relapsed_b_cell_non_hodgkin_lymphoma_20261116,
  title        = {Relapsed B-Cell Non Hodgkin Lymphoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/relapsed-b-cell-non-hodgkin-lymphoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_relapsed_b_cell_non_hodgkin_lymphoma_20261116","title":"Relapsed B-Cell Non Hodgkin Lymphoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/relapsed-b-cell-non-hodgkin-lymphoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
